OYOphelia Q. P. Yin

Ophelia Q. P. Yin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ophelia Q. P. Yin has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Moses S. S. Chow

    Department of Pharmacy, Grantham Hospital, Aberdeen, Hong Kong

    3 shared publications
  • B. Tomlinson

    School of Pharmacy Faculty of Medicine Department of Pharmacy The Chinese University of Hong Kong Huashan Hospital Fudan University China (X

    1 shared publication
  • Moses S.S Chow

    1 shared publication
  • Sherry S. L. Lam

    School of Pharmacy and Drug Development Centre, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N. T., Hong Kong

    1 shared publication
  • So‐Kei Lau

    School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong

    1 shared publication
  • X. J. Shi

    1 shared publication

Latest Publications

  • Population Pharmacokinetics of Cyclosporine in Chinese Cardiac Transplant Recipients

    by Ophelia Q. P. Yin, So‐Kei Lau, Moses S. S. Chow

    Study Objective. To characterize the population pharmacokinetics of cyclosporine in Chinese patients undergoing cardiac transplantation and to identify the demographic and clinical covariates affecting cyclosporine clearance.Design. Population pharmacokinetic analysis using data from a retrospective chart review.Setting. Specialty hospital in Hong Kong for treatment of cardiac and pulmonary diseases.Patients. Thirty‐eight Chinese adult patients (mean age 46 yrs) who had undergone routine cyclosporine therapeutic drug monitoring after cardiac transplantation between January 1, 1991, and December 31, 2003.Measurements and Main Results. Data regarding dosing, demographics, clinical laboratory values, and concurrent drugs were collected retrospectively. Data were included if patients had blood cyclosporine concentrations determined for at least 12 weeks after transplantation; an average of 18 blood samples/patient were collected. Population modeling was performed using a one‐compartment linear model with first‐order absorption and elimination. Various demographic and clinical covariates were tested for their significant effects on the apparent oral clearance (Cl/F) of cyclosporine. The stability of the final population model was evaluated by using the bootstrap resampling method. Statistically significant associations were observed between Cl/F and each of the following covariates: body weight (BW), use of diltiazem (DIL), and hematocrit value (HCT). The final model was Cl/F = 5.00 • (1 ‐ DIL) + 365/HCT + (0.144 • BW). The interindividual variabilities of Cl/F and apparent volume of distribution were 14.5% and 40.2%, respectively. The mean parameter estimates obtained from bootstrap analyses were highly consistent with those obtained with the original data set.Conclusion. The estimated Cl/F values of cyclosporine in our Chinese cardiac transplant recipients appeared to be similar to those reported for Caucasian cardiac transplant recipients. Thus, our data provide support that a cyclosporine dosage regimen similar to that in Caucasian patients may be needed in Chinese cardiac transplant recipients. However, further studies are required to determine the optimum cyclosporine dosage regimen in the Chinese population.


  • Open Access

    EFFECT OF CYP2D6*10 ALLELE ON THE PHARMACOKINETICS OF LORATADINE IN CHINESE SUBJECTS

    by Ophelia Q. P. Yin, X. J. Shi, B. Tomlinson, Moses S. S. Chow

    Loratadine is known to be a substrate for both CYP3A4 and CYP2D6 based on a previous in vitro study. In view of the large interindividual variability in loratadine pharmacokinetics and the greater genetically determined variability of CYP2D6 activity than of CYP3A4 in vivo, we hypothesized that CYP2D6 polymorphisms may contribute to the pharmacokinetic variability of loratadine. The purpose of this study was to evaluate the effect of CYP2D6 genotype (specifically the CYP2D6*10 allele) on the pharmacokinetics of loratadine in Chinese subjects. Three groups of healthy male Chinese subjects were enrolled: group I, homozygous CYP2D6*1 (*1/*1, n = 4); group II, heterozygous CYP2D6*10 (*1/*10 or *2/*10, n = 6); and group III, homozygous CYP2D6*10 (*10/*10, n = 7) carriers. Each subject received a single oral dose of 20 mg of loratadine under fasting conditions. Multiple blood samples were collected over 48 h, and the plasma concentrations of loratadine and its metabolite desloratadine were determined by high-performance liquid chromatography. In comparing homozygous CYP2D6*10 (group III) to heterozygous CYP2D6*10 (group II) to homozygous CYP2D6*1 (group I) subjects, loratadine oral clearance values were 7.17 ± 2.54 versus 11.06 ± 1.70 versus 14.59 ± 2.43 l/h/kg, respectively [one-way analysis of variance (ANOVA), p < 0.01], and the corresponding metabolic ratios [area under the plasma concentration-time curve (AUC)desloratadine/AUCloratadine] were 1.55 ± 0.73 versus 2.47 ± 0.46 versus 3.32 ± 0.49, respectively (one-way ANOVA, p < 0.05), indicating a gene-dose effect. The results demonstrated that CYP2D6 polymorphism prevalent in the Chinese population significantly affected loratadine pharmacokinetics.


  • Simultaneous determination of paracetamol and dextropropoxyphene in human plasma by liquid chromatography/tandem mass spectrometry: application to clinical bioequivalence studies

    by Ophelia Q. P. Yin, Sherry S. L. Lam, Moses S. S. Chow

    A liquid chromatography/mass spectrometry method for simultaneous determination of paracetamol and dextropropoxyphene in human plasma is described. Paracetamol and dextropropoxyphene, together with their internal standards (tolbutamide and pyrroliphene), were extracted from 0.5 mL of plasma using solid‐phase extraction. The chromatography was performed using a Thermo Hypersil APS‐2 Amino column (250 mm × 4.6 mm, 5 μm) with a mobile phase consisting of acetonitrile and 0.4% glacial acetic acid in water (20:80). The total run time was 6 min for each sample. The triple‐quadrupole mass spectrometer was operated in both positive (for detection of dextropropoxyphene and its IS pyrroliphene) and negative (for detection of paracetamol and its IS tolbutamide) modes using a polarity‐switching technique. Multiple reaction monitoring was used for quantification. The method was linear over the concentration range of 0.1–20 μg/mL for paracetamol and 0.5–80 ng/mL for dextropropoxyphene. The intra‐ and inter‐day precision were less than 10%, and the accuracy ranged from 92.2–110.9%. The lower limits of quantification were 0.1 μg/mL for paracetamol and 0.5 ng/mL for dextropropoxyphene. The present method provides a robust, fast and sensitive analytical tool for both paracetamol and dextropropoxyphene, and has been successfully applied to a clinical bioequivalence study in 14 subjects. Copyright © 2005 John Wiley & Sons, Ltd.